!
!
Sign in / Join ICS
Home
Darifenacin provides meaningful improvements to patients dissatisfied with oxybutynin or tolterodine therapy
Newman D
1
, Koochaki P
2
, Fix D
2
Abstract Category
Neurourology: Clinical
Abstract 454
Non-Discussion Posters
Scientific Non Discussion Poster Session 32
1.
University of Pennsylvania,
2.
Procter & Gamble Pharmaceuticals
Links
Abstract PDF
Edit Abstract
Abstract Centre
Abstract
09/11/2024 18:01:36